Wednesday, May 13, 2026 This long-term follow-up of RELEVANCE confirmed that R2 provides a chemo-free alternative to immunochemotherapy in this patient population. Lenalidomide plus rituximab (\(R^{2}\)) is a comparable, chemotherapy-free alternative to standard immunochemotherapy (R-CHOP/R-B/R-CVP) for previously untreated advanced follicular lymphoma. Long-term follow-up showed similar 6-year and 10-year progression-free survival rates, Gower N, Feugier P, Westin JR, Schiano de Colella J-MS, Tilly H, Palomba ML, Julia E, Damaj GL, Durand A, Flinn IW, Lemonnier F, Morineau N, Ysebaert L, Bartlett N, Thieblemont C, Ribrag V, Gastinne T, Arthur D, Fouillet L, Guidez S, Houot R, da Silva MG, Barnes J, Bijou F, Cartron G, Martin Garcia-Sancho AM, Eradat HA, Cheminant M, López-Guillermo AL, Abrisqueta P, Abraham J, Sarkozy C, Izutsu K, Crochet G, Sehn LH, Gkasiamis A, Yge M-L, Chartier L, Fowler NH, Xerri L, Salles GA, Morschhauser F. Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis (ONLINE). Blood 2026.https://doi.org/10.1182/blood.2026033126 Trial registration: NCT01476787 and NCT01650701; EudraCT: 2011-002792-42
